Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study

Ergür, Figen Öztürk; Yildiz, Murat; Sener, Melahat Uzel; Kavurgaci, Suna; Ozturk, Ayperi.
São Paulo med. j ; 140(3): 372-377, May-June 2022. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1377393

Documentos relacionados

  1. Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study.
  2. Assessment of chemotherapy-related educational needs of colorectal cancer patients.
  3. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
  4. Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
  5. Pharmacogenetic Approach for the Prevention of Rivaroxaban's ADRs: A Systematic Review and Meta-Analysis.
  6. Immunosuppressive agents in the treatment of IgA nephropathy: A meta-analysis of clinical randomized controlled literature.
  7. On the receiving end: have patient perceptions of the side-effects of cancer chemotherapy changed since the twentieth century?
  8. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
  9. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
  10. Uso de Ivermectina e Atazanavir no tratamento da Covid-19: uma revisão de escopo